**INFORMATION DISCLOSURE STATEMENT**

Applicant : Andersson, et al.
App. No : 10/601,070
Filed : June 20, 2003
For : N-SUBSTITUTED PIPERIDINE
DERIVATIVES AS SEROTONIN
RECEPTOR AGENTS
Examiner : Charanjit Aulakh
Art Unit : 1625

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

May 24, 2006

(Date)

Daniel Hart, Reg. No. 40,637

Mail Stop RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing one hundred five (105) references to be considered by the Examiner. Also enclosed are eighty-six (86) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

With respect to Reference 22, an English translation was not available. However, U.S. Patent No. 5,025,013 (Reference 6) is believed to contain the relevant portions in English.

With respect to Reference 27, an English translation was not available. However, the relevant portion is believed to be the chemical structures shown throughout the article.

With respect to Reference 61, an English translation was not available. However, the relevant portion is believed to be the chemical structures shown throughout the article.


Appl. No. : 10/601,070
Filed : June 20, 2003

Docket No. ACADIA.020A
Customer No. 20,995

Please place these references in the file of the above-identified patent application in accordance with 37 C.F.R. § 1.97(i).

Respectfully submitted,
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: May 24, 2006

By: 
Daniel Hart
Registration No. 40,637
Attorney of Record
Customer No. 20,995
(619) 235-8550

2624785
052306


INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 6

Application No.	10/601070
Filing Date	June 20, 2003
First Named Inventor	Andersson, et al.
Art Unit	1625
Examiner	Charanjit Aulakh
Attorney Docket No.	ACADIA.020A



U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	3,983,234	09-28-1976	Sayers	
	2	4,138,492	02-06-1979	Noverola, et al.	
	3	4,255,432	03-10-1981	Kluge, et al.	
	4	4,353,900	10-12-1982	Clark	
	5	4,367,232	01-04-1983	Boix-Iglesias, et al.	
	6	5,025,013	06-18-1991	Barreau et al.	
	7	5,461,066	10-24-1995	Gericke	
	8	5,795,894	08-18-1998	Shue, et al.	
	9	5,869,488	02-09-1999	Shue, et al.	
	10	5,877,173	03-02-1999	Olney, et al.	
	11	5,912,132	06-15-1999	Brann	
	12	5,955,281	09-21-1999	Brann	
	13	6,107,324	08-22-2000	Behan, et al.	
	14	6,140,509	10-31-2000	Behan, et al.	
	15	6,150,393	11-21-2000	Behan, et al.	
	16	6,911,452	06-28-2005	Schlienger, N.	
	17	2002/0004513 A1	01-10-2002	Andersson, et al.	
	18	2004/0006081	01/08/2004	Burrows, et al.	
	19	2002-0165225 A1	11-07-2002	Hamied, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	20	CA 984843	03/02/1976	Wyeth, et al.		
	21	EP 0061333	09-29-1982	Syntex		
	22	EP 0379441	07-25-1990	Rhone-Poulenc Sante		
	23	EP 0005318	11-14-1979	Janssen Pharm.		
	24	EP 0548015	06-23-1993	Borzetta, et al.		
	25	EP 0625507	11-23-1994	Nishin Flour Milling		

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/601070
	Filing Date	June 20, 2003
	First Named Inventor	Andersson, et al.
	Art Unit	1625
(Multiple sheets used when necessary)	Examiner	Charanjit Aulakh
SHEET 2 OF 6	Attorney Docket No.	ACADIA.020A

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	26	WO 94/27967	12-18-1994	Smithkline		
	27	HU 157325	03-19-1998	Rudolf, et al.		
	28	WO 97/11940	04-03-1997	Fisher, et al.		
	29	WO 97/38665	10-23-1997	Merck & Co.,		
	30	WO 97/38984	10-23-1997	Dupont Merck Pharma.		
	31	WO 98/17646	10-15-1997	Pieper		
	32	WO 97/08166	03-06-1997	Schering Corp.		
	33	WO 98/50534	11-12-1998	Smithkline Beecham		
	34	WO 98/11128	03-19-1998	Rudolf, et al.		
	35	WO 99/52927	10-21-1999	Behan		
	36	WO 00/69810	11-23-2000	Ling, et al.		
	37	WO 00/23076	04-27-2000	Suntory Limited		
	38	WO 00/59497	10-12-2000	Merck & Co.,		
	39	WO 01/44191	06-21-2001	Thurieu, et al.		
	40	WO 00/56335	09-28-2000	Ellman, et al.		
	41	WO 02/079186	10-10-2002	Hoffman, et al.		
	42	WO 01/87839	09/13/2001	Astrazeneca AB		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	43	Adam, et al. <i>Psychopharmacology</i> . (1989) 99 (2) 219-221	bA
	44	Bakshi, et al., <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 271 No. 2 (1994) pp 787-794.	
	45	Barr, et al. <i>The Journal of biological Chemistry</i> , Vol. 272 No. 52, (1997) pp. 32979-32987.	
	46	Bassus, et al. <i>Bur. J. Med. Chem, Chimica Therapetuica</i> , July-August 1974 pp 416-423	
	47	Bennett, et al. <i>Neurology</i> 43, August 1993 pp. 1551-1555.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/601070
	Filing Date	June 20, 2003
	First Named Inventor	Andersson, et al.
	Art Unit	1625
(Multiple sheets used when necessary)	Examiner	Charanjit Aulakh
SHEET 3 OF 6	Attorney Docket No.	ACADIA.020A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	48	Bhatia, et al. <i>J. Med Chem.</i> , 1996, 39, pp. 3938-3950	
	49	Bibbiani, et al. <i>Neurology</i> 57, 2001 pp. 1829-1834.	
	50	Blakley et al. <i>The Journal of Pharmacology and Experimental Therapeutics</i> (2001) 299(1) 277-289	
	51	Blier et al. <i>J. of Psychiatry & Neuroscience</i> (2001) 26(1) 37-43	
	52	Boullin, D. J. (Ed.). <i>Serotonin in Mental Abnormalities, Biochemical Indicators of Central Serotonin Function</i> , 1978, John Wiley: New York.	
	53	Birkmayer, et al, <i>Journal of Neural Transmission</i> 35, pp. 93-116 (1974)	
	54	Butcher, et al. <i>Letters to the Editor, J. Pharm Pharmac</i> (1970) 22 , pp. 313-316	
	55	Caroon, et al. <i>J. Med. Chem.</i> (1981) 24, 1320-1326	
	56	Clark, et al. <i>J. Med. Chem.</i> Vol. 26, pp. 855-861 (1983)	
	57	DeClerck, et al. <i>Current Therapeutic Research</i> , (1987) 41 4 427:432	
	58	Delecluse, et al. <i>Movement Disorders</i> , Vol. 13, No. 5 1998 pp. 846-847	
	59	Durif, et al. <i>Neurology</i> 48 1997 pp. 658-662	
	60	Eichelbaum, et al. <i>Clinical and Experimental Pharmacology and Physiology</i> (1996) 23 pp, 983-985.	
	61	Ermakov et. al. Use of Mass spectrometry in Structural and stereochemical studies (1981)	
	62	Everett, et al. <i>Science</i> Vol. 168 May 1970 pp. 849-850	
	63	Factor, et al. <i>Movement Disorders</i> Vol 7 No. 2 1992 pp. 125-131	
	64	Factor, et al. <i>Movement Disorders</i> Vol 16 No. 1 2001 pp. 135-139.	
	65	Fisera, et al. <i>Monatshefte Fur Chemie</i> 125 (1994) pp. 909-919	
	66	Friedman, <i>Movement Disorders</i> Vol 9 No. 3 1994 pp. 321-324.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/601070
	Filing Date	June 20, 2003
	First Named Inventor	Andersson, et al.
	Art Unit	1625
(Multiple sheets used when necessary)	Examiner	Charanjit Aulakh
SHEET 4 OF 6	Attorney Docket No.	ACADIA.020A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	67	Freidman, et al. <i>Movement Disorders</i> Vol 15 No. 2 2000 pp. 201-211	
	68	Fuller, <i>Biology of Serotonin Transmission</i> , 1982, Chapter 9, pp. 221-247.	
	69	Gainetdivnov, et al. <i>Trends in Neuroscience</i> (2001) 24(9) 527-533	
	70	Gamma, <i>Neuropsychopharmacology</i> 2000, Vol. 23, No. 4, pp. 388-395	
	71	Gawley, R. E. and Jeffrey Aube (Eds.). <i>Principles of Asymmetric Synthesis</i> , 1996, Elsevier Science Ltd.: New York	
	72	Gershon, et al. <i>The Peripheral Actions of 5-Hydroxyptamine</i> , 1989, Chapter 11, pp. 246-273	
	73	Gstach, et al. <i>Papers</i> , September 1990 pp. 803-808.	
	74	Harper, et al. <i>J. Medicinal Chemistry</i> , April 1964. vol. 7, pp. 729-732.	
	75	Herrick-Davis, et al. <i>The Journal of Pharmaocology and Experimental Therapeutics</i> , 2000, vol. 295 No. 1 pp. 226-232.	
	76	Idzikowski, et al. <i>Br J. Clin. Pharmacol</i> , (1991) 31 (2) : 193-6.	
	77	Julius, et al. <i>Neurobiology</i> , Vol. 87, pp. 928-932 1990	
	78	Landolt HP, et al. <i>Neuropsychopharmacolgy</i> (1999) 21 (3) 455-466	
	79	Leysen, et al. <i>Nature</i> , Vol 272, 9 March 1978, pp. 171.	
	80	Liechti, et . al. <i>Neuropsychopharmacology</i> 2001, Vol. 24, No. 3, pp. 240-252.	
	81	Linder, et al. <i>Clinical Chemistry</i> , vol 43, 2, pp 1997 pp. 254-266	
	82	Mansbach, et al. <i>Psychopharmacology</i> , (1988) 94, pp. 507-514.	
	83	Mavunkel, et al. <i>J. Med. Chem</i> (1996), vol 39, pp. 3169-3173.	
	84	Mayer, et al. <i>Pharmacopsychiatry</i> (2003) 36: 150-155	
	85	Metizer, et al. <i>Neuropsychopharmacology</i> (1995) 12, 39-45	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/601070
	Filing Date	June 20, 2003
	First Named Inventor	Andersson, et al.
	Art Unit	1625
(Multiple sheets used when necessary)	Examiner	Charanjit Aulakh
SHEET 5 OF 6	Attorney Docket No.	ACADIA.020A

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	86	Meng, et al. <i>Tetrahedron</i> , vol 47, No. 32 pp. 6251-6251, (1991)	
	87	Miyata et al. <i>J. of Cardiovascular Pharmacology</i> (2000) 35(2) 294-301	
	88	Mullen, et al. <i>J. Med. Chem</i> (2000), vol 43, pp. 4045-4050.	
	89	Ng, et al. <i>Science</i> , Vol. 170, (1970) pp. 76-77	
	90	Nordstrom, et al. <i>Psychopharmacology</i> , (1993) vol. 110, pp. 365-367	
	91	Pace, et al. <i>Proc. Natl. Acad. Sci</i> , Vol 88, (1991) pp. 7031-7035.	
	92	Paiva, et al. <i>Psychopharmacology (Berl)</i> 1988, 96 (3) 395-9	
	93	Sadzot, et al. <i>Psychopharmacology</i> , (1989) vol. 98 pp. 495-499.	
	94	Sharpley, et al. <i>Neuropharmacology</i> (1994), 33, (3-4), 467-71.	
	95	Schins et al. <i>Psychosomatic Medicine</i> (2003) 65:729-737	
	96	Smith, et al. <i>J. Med. Chem.</i> (1995), vol 38, pp. 3772-3779.	
	97	The Parkinson Study Group. 1999. <i>Low-Dose Clozapine for the Treatment for Drug-Induced Psychosis in Parkinson's Disease</i> , vol. 340(10):757-763.	
	98	The French Study Group. 1999. <i>Clozapine in Drug-Induced Psychosis in Parkinson's Disease</i> , <i>The Lancet</i> , 353:2041-2042.	
	99	Tsukamoto, et al. <i>Chem. Pharm Bull.</i> 43 (1995) pp. 1523-1529.	
	100	Vallar, et al. <i>Nature</i> , Vol 330, December 1987, pp. 566-568.	
	101	Van Laar, et al. <i>Psychopharmacology</i> (2001), 154(2) 189-97	
	102	Viola, et al. <i>Clin Neurophysio</i> 2002 113(3): 429-34	
	103	Wade, et al. <i>J. Comb. Chem.</i> 2000 2, pp. 266-275	
	104	Yoshida, et al. <i>Clinical Neuropharmacology</i> , Vol. 21, No. 1 pp 68-69.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/601070
	Filing Date	June 20, 2003
	First Named Inventor	Andersson, et al.
	Art Unit	1625
(Multiple sheets used when necessary)	Examiner	Charanjit Aulakh
SHEET 6 OF 6	Attorney Docket No.	ACADIA.020A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	105	Chemical Abstracts, (25305) vol. 73, 1970, p. 350	

2599818
051506

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.